2. Anti-infection Vitamin D Related/Nuclear Receptor Membrane Transporter/Ion Channel
  3. Bacterial Estrogen Receptor/ERR FATP
  4. (Z)-Ligustilide

(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer.

For research use only. We do not sell to patients.

CAS No. : 81944-09-4

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
20 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of (Z)-Ligustilide:

(Z)-Ligustilide Related Antibodies

Top Publications Citing Use of Products
IF
Cell Proliferation/Viability Assay
WB
Microbiological Assay
In Vivo Efficacy Study
RT-PCR

    (Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494.  [Abstract]

    IF double staining for PINK1 (green) and Iba-1 (red) in the hippocampal CA1 region, and semi-quantitation in bar chart. Scale bar = 75 µm, n = 6. IF staining revealed an increase in the colocalization of PINK1 and Iba-1 in the hippocampal CA1 region following (Z)-Ligustilide (Z-LIG, 10-40 mg/kg; i.p.; 12 days) administration.

    (Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494.  [Abstract]

    Expression of PINK1 by WB and semi-quantitation in bar chart (n = 5). WB results demonstrated that (Z)-Ligustilide (Z-LIG, 10-40 mg/kg; i.p.; 12 days) dose-dependently upregulated the level of PINK1 (p < 0.01).

    (Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494.  [Abstract]

    Immobile times in the FST (n = 10). The results demonstrated that (Z)-Ligustilide (Z-LIG, 10-40 mg/kg; i.p.; 12 days) markedly reduced the immobility duration in adolescent rats (p < 0.01).

    (Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Dec:149:157494.  [Abstract]

    The relative mRNA levels of IL-1β, IL-6 and IL-4, IL-10 in BV2 cells by (Z)-Ligustilide (Z-LIG, 10, 20, 40 µM; 15 h) (n = 6). Real-time PCR analysis revealed that treatment with 20 and 40 μM Z-LIG significantly inhibited the mRNA expression of pro-inflammatory cytokines IL-6 and TNF-α while promoting the expression of the anti-inflammatory cytokines IL-4 and IL-10.

    (Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2024 Sep 23:298:110260.  [Abstract]

    N2a cells were treated with a series of concentrations of (Z)-Ligustilide for 24 h; cell viability was determined with the Cell Counting Kit-8 (CCK-8), and the cytotoxic concentration 50% (CC50) was calculated. The results indicated that the CC50 of (Z)-Ligustilide in N2a cells was 429.9 μM.

    (Z)-Ligustilide purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2024 Sep 23:298:110260.  [Abstract]

    N2a cells were treated with a series of concentrations of (Z)-Ligustilide for 24 h, supernatants were harvested, virus titers were determined, and the viral inhibitory concentration 50% (IC50) was calculated separately (n=3). The results indicated that the IC50 of (Z)-Ligustilide for RABV infection on N2a cells was 71.93 μM.

    View All Estrogen Receptor/ERR Isoform Specific Products:

    View All Isoforms
    Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    (Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6[1]. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) [2]. (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer[3].

    IC50 & Target

    ERα

     

    In Vitro

    Z-ligustilide (25 and 100 µM, 24 hours) can effectively inhibit oleic acid-induced lipid accumulation in HepG2 cells, suppress fatty acid uptake and esterification, and has potential anti-fatty liver effects[2].
    Z-ligustilide (10-50 μM, 72 hours) can significantly enhance the sensitivity of ERα-negative breast cancer cells to Tamoxifen (HY-13757A) by restoring the expression of ERα[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    (Z)-Ligustilide Related Antibodies

    Real Time qPCR[2]

    Cell Line: HepG2 cells
    Concentration: 25 and 100 µM
    Incubation Time: 24 h
    Result: Dose-dependently reduced the mRNA expression of FATP5 and DGAT2 genes.

    Western Blot Analysis[2]

    Cell Line: HepG2 cells
    Concentration: 25 and 100 µM
    Incubation Time: 24 h
    Result: Significantly reduced the expression level of DGAT2 protein.

    Cell Cycle Analysis[3]

    Cell Line: MDA-MB-231, MDA-MB-453, HS578t cells
    Concentration: 10, 25, 50 μM
    Incubation Time: 72 h
    Result: After co-administration with Tamoxifen (HY-13757A), significantly inhibited cell proliferation, promoted cell apoptosis, and induced cell cycle arrest in the S phase and G2/M phase.
    In Vivo

    Z-ligustilide (50 mg/kg, p.o., once daily for 6 weeks) significantly reduces hepatic lipid accumulation in high-fat diet-induced fatty liver mice, inhibiting fatty acid uptake and esterification, demonstrating potential application value for non-alcoholic fatty liver disease (NAFLD)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: High-fat diet (HFD)-induced fatty liver model in male C57BL/6 mice[2]
    Dosage: 50 mg/kg
    Administration: Oral gavage (p.o.), once daily for 6 weeks
    Result: Significantly reduced high-fat diet (HFD)-induced hepatic fat accumulation in mice, as confirmed by hepatic TG assay, H&E staining, and Oil Red O staining, showing a marked decrease in liver lipid content.
    Significantly inhibited the expression of fatty acid uptake-related genes CD36 and DGAT2, and reduced the expression of SREBP1c and its downstream target genes FAS and SCD1, thereby decreasing lipid production in the liver.
    Molecular Weight

    190.24

    Formula

    C12H14O2
    CAS No.
    Appearance

    Liquid (Density: 1.10±0.1 g/cm3)

    Color

    Colorless to light yellow

    SMILES

    O=C1O/C(C2=C1C=CCC2)=C\CCC
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    -20°C, protect from light, stored under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (525.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.2565 mL 26.2826 mL 52.5652 mL
    5 mM 1.0513 mL 5.2565 mL 10.5130 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (13.14 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.11%

    SDS (480 KB)

    COA (265 KB) HNMR (243 KB) RP-HPLC (210 KB) MS (86 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 5.2565 mL 26.2826 mL 52.5652 mL 131.4129 mL
    5 mM 1.0513 mL 5.2565 mL 10.5130 mL 26.2826 mL
    10 mM 0.5257 mL 2.6283 mL 5.2565 mL 13.1413 mL
    15 mM 0.3504 mL 1.7522 mL 3.5043 mL 8.7609 mL
    20 mM 0.2628 mL 1.3141 mL 2.6283 mL 6.5706 mL
    25 mM 0.2103 mL 1.0513 mL 2.1026 mL 5.2565 mL
    30 mM 0.1752 mL 0.8761 mL 1.7522 mL 4.3804 mL
    40 mM 0.1314 mL 0.6571 mL 1.3141 mL 3.2853 mL
    50 mM 0.1051 mL 0.5257 mL 1.0513 mL 2.6283 mL
    60 mM 0.0876 mL 0.4380 mL 0.8761 mL 2.1902 mL
    80 mM 0.0657 mL 0.3285 mL 0.6571 mL 1.6427 mL
    100 mM 0.0526 mL 0.2628 mL 0.5257 mL 1.3141 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    (Z)-Ligustilide Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    (Z)-Ligustilide81944-09-4BacterialEstrogen Receptor/ERRFATPFatty acid transport proteinNon-alcoholic fatty liver diseaseHepG2 cells High-fat diet (HFD)-induced fatty liver modelInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    (Z)-Ligustilide
    Cat. No.:
    HY-N0401A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Korean - KR (480 KB) Portuguese - PT (480 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.